Nature Communications (Feb 2019)
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
- Jennifer L. Caswell-Jin,
- Katherine McNamara,
- Johannes G. Reiter,
- Ruping Sun,
- Zheng Hu,
- Zhicheng Ma,
- Jie Ding,
- Carlos J. Suarez,
- Susanne Tilk,
- Akshara Raghavendra,
- Victoria Forte,
- Suet-Feung Chin,
- Helen Bardwell,
- Elena Provenzano,
- Carlos Caldas,
- Julie Lang,
- Robert West,
- Debu Tripathy,
- Michael F. Press,
- Christina Curtis
Affiliations
- Jennifer L. Caswell-Jin
- Department of Medicine, Division of Oncology, Stanford University School of Medicine
- Katherine McNamara
- Department of Medicine, Division of Oncology, Stanford University School of Medicine
- Johannes G. Reiter
- Canary Center for Cancer Early Detection, Department of Radiology, Stanford University School of Medicine
- Ruping Sun
- Department of Medicine, Division of Oncology, Stanford University School of Medicine
- Zheng Hu
- Department of Medicine, Division of Oncology, Stanford University School of Medicine
- Zhicheng Ma
- Department of Medicine, Division of Oncology, Stanford University School of Medicine
- Jie Ding
- Department of Medicine, Division of Oncology, Stanford University School of Medicine
- Carlos J. Suarez
- Department of Pathology, Stanford University School of Medicine
- Susanne Tilk
- Department of Biology, Stanford University
- Akshara Raghavendra
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
- Victoria Forte
- Maimonides Medical Center
- Suet-Feung Chin
- Cancer Research UK Cambridge Institute, Department of Oncology, University of Cambridge
- Helen Bardwell
- Cancer Research UK Cambridge Institute, Department of Oncology, University of Cambridge
- Elena Provenzano
- Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust
- Carlos Caldas
- Cancer Research UK Cambridge Institute, Department of Oncology, University of Cambridge
- Julie Lang
- Norris Comprehensive Cancer Center
- Robert West
- Department of Pathology, Stanford University School of Medicine
- Debu Tripathy
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
- Michael F. Press
- Norris Comprehensive Cancer Center
- Christina Curtis
- Department of Medicine, Division of Oncology, Stanford University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-019-08593-4
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 12
Abstract
When examining the evolution of treatment resistance in breast cancer, perceived genomic changes may be due to clonal evolution or heterogeneous tumors. Here, the authors show that apparent clonal change can in fact be due to pre-treatment heterogeneity, and samples from at least two regions are necessary to detect treatment-induced clonal shifts
